Previous close | 1.1000 |
Open | 2.3000 |
Bid | 0.1000 |
Ask | 0.9500 |
Strike | 110.00 |
Expiry date | 2024-09-20 |
Day's range | 1.1000 - 2.3000 |
Contract range | N/A |
Volume | |
Open interest | 43 |
The robust performance of Insulet's (PODD) Omnipod 5 raises investors' optimism. However, concerns remain over the macroeconomic impacts and the company's overdependence on a single platform.
Director Timothy Scannell of Insulet Corp (NASDAQ:PODD) sold 7,000 shares of the company on June 10, 2024, according to a recent SEC Filing.
ACTON, Mass., May 28, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the Jefferies Global Healthcare Conference in New York City on Thursday, June 6, 2024 at 9:00 a.m. (Eastern Time).